GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Arcutis Biotherapeutics ARQT · USD

Health Care · US listing · 🇺🇸 United States

Compare

26.20

+2.54%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$376.1m

FY2017FY2025

Net income

−$16.1m

FY2017FY2025

Free cash flow

−$6.3m

FY2017FY2025

Shareholders' equity

$189.5m

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue$376.1m$196.5m$59.6m$3.7m—————
Gross profit$339.4m$177.4m$54.6m$2.9m−$763,000−$455,000−$195,000——
Research and development$77.1m$76.4m$110.6m$182.4m$145.6m$115.3m$36.5m$17.9m$3.4m
Operating income−$11.8m−$112.2m−$230.2m−$295.8m−$206.5m−$136.6m−$43.1m−$19.7m−$4.1m
Net income−$16.1m−$140.0m−$262.1m−$311.5m−$205.9m−$135.7m−$42.0m−$19.3m−$5.0m
Diluted earnings per share-0.12-1.16-2.83-5.11-4.10-3.16-1.10-0.53-4.98

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$433.0m$348.9m$341.4m$449.3m$408.2m$298.3m$107.0m$51.1m$3.8m
Cash and short-term investments$221.0m$228.0m$271.9m$409.6m$388.6m$284.4m$101.3m$50.9m$3.4m
Total liabilities$243.5m$191.3m$252.7m$239.7m$110.5m$27.6m$5.5m$75.1m$8.8m
Debt$109.0m$107.2m$201.8m$197.8m$72.4m———$1.0m
Shareholders' equity$189.5m$157.5m$88.7m$209.6m$297.7m$270.6m$101.5m−$24.0m−$5.0m
Shares outstanding136m121m93m61m50m43m38m36m1m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$5.6m−$112.2m−$247.1m−$257.7m−$174.6m−$113.0m−$42.8m−$14.1m−$3.8m
Capital spending−$686,000−$143,000−$428,000−$23.3m−$995,000−$321,000−$295,000−$295,000−$295,000
Free cash flow−$6.3m−$112.3m−$247.5m−$281.0m−$175.6m−$113.4m−$43.1m−$14.4m−$4.1m
Dividends paid———−$122.8m−$72.3m————

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$129.9m$105.4m$129.5m$99.2m$81.5m$65.8m$71.4m$44.8m
Gross profit$118.9m$95.6m$117.8m$90.5m$74.0m$57.0m$64.5m$39.3m
Operating income$16.4m−$9.1m$18.4m$8.5m−$12.5m−$21.8m−$7.6m−$34.9m
Net income$15.0m−$11.3m$17.4m$7.4m−$15.9m−$25.1m−$10.8m−$41.5m
Diluted earnings per share0.11-0.080.130.05-0.12-0.18-0.09-0.34
Cash from operations$12.0m$2.0m$26.0m−$1.0m—−$30.0m—−$34.0m
Capital spending——————−$5.0m—
Total assets$488.5m$460.0m$433.0m$371.0m$352.4m$344.1m$348.9m$437.4m
Cash and short-term investments$238.6m$224.0m$221.0m$191.1m$191.1m$198.1m$228.0m$330.6m
Debt$108.9m$109.4m$109.0m$108.5m$108.0m$108.5m$108.0m$205.4m
Shareholders' equity$220.6m$189.6m$189.5m$158.1m$139.0m$142.7m$157.5m$156.6m

Financial ratios

Data as of 23 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin90.2%90.3%91.6%79.5%———
Operating margin-0.8%-57.1%-384.7%-8025.1%———
Net margin-4.3%-71.3%-439.8%-8449.8%———
Return on equity-8.5%-88.9%-295.6%-148.6%-69.2%-50.1%—
Return on assets-3.7%-40.1%-76.8%-69.3%-50.4%-45.5%—
Free cash flow yield-0.1%-2.9%-8.3%-11.9%-10.7%-8.1%—
Revenue growth91.3%229.7%1517.1%————
Earnings growth-88.5%-46.6%-15.8%51.3%51.8%223.1%—
Current ratio3.17x4.15x7.08x11.57x12.09x12.96x—
Debt to equity0.58x0.69x2.28x0.95x0.24x—0.00x
Equity ratio43.8%45.2%26.0%46.6%72.9%90.7%—
Interest coverage-0.24x-4.13x-7.72x-18.90x-454.91x——
R&D as a share of sales20.5%38.9%185.5%4949.4%———
Buybacks as a share of market value-12.1%-30.7%-51.9%-21.4%-16.8%-12.8%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue367.3%——
Operating income-65.8%-38.7%—
Net income-62.7%-34.7%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin90.3%90.3%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-244.0-12.0-1.1-2.9-5.1-8.9
Price to sales10.58.65.0244.8——

Market value over time

31 Jan 2020 to 22 Oct 2026, in USD

$43.6m$4.38bn

Share price return

Finished calendar years

202520242023202220212020
Return107%423%-83%-15%-40%33%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.